Clark Virginia, Nelson David R
Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Florida, Gainesville, FL 32610, USA.
Clin Liver Dis. 2009 Aug;13(3):351-63. doi: 10.1016/j.cld.2009.05.004.
The current standard of care for treatment of hepatitis C is pegylated interferon and ribavirin. Despite the large number of new oral agents under development, interferon will likely remain the backbone of future therapy. Interferon has unique antiviral and immunomodulatory properties, which have been critical in limiting resistance to protease inhibitors and improving efficacy. Hence, optimizing pharmacokinetics and promoting adherence to interferon dosing regimens will become even more critical as new regimens enter the clinical arena. This review highlights novel interferons under development that may offer therapeutic advantages over the formulations currently available.
目前丙型肝炎治疗的标准护理方案是聚乙二醇化干扰素和利巴韦林。尽管有大量新型口服药物正在研发中，但干扰素可能仍将是未来治疗的主要药物。干扰素具有独特的抗病毒和免疫调节特性，这对于限制对蛋白酶抑制剂的耐药性和提高疗效至关重要。因此，随着新的治疗方案进入临床领域，优化干扰素的药代动力学并提高对其给药方案的依从性将变得更加关键。本综述重点介绍了正在研发的新型干扰素，这些干扰素可能比目前可用的制剂具有治疗优势。
